Multi-Dose Priming Regimens of PfSPZ Vaccine: Safety and Efficacy against Controlled Human Malaria Infection in Equatoguinean Adults
Authors:
- Said Abdallah JongoSJSaid Abdallah Jongo
- L. W. Preston ChurchLCL. W. Preston Church
- Vicente Urbano Nsue Ndong NchamaVNVicente Urbano Nsue Ndong Nchama
- Ali HamadAHAli Hamad
- Raul ChuquiyauriRCRaul Chuquiyauri
- Kamaka Ramadhani KassimKamaka Ramadhani Kassim
- Thabit AthumanTAThabit Athuman
- Anna DealADAnna Deal
- Kc NatashaKNKc Natasha
- Ali MtoroAMAli Mtoro
- Maxmillian MpinaMMMaxmillian Mpina
- Elizabeth NyakarunguENElizabeth Nyakarungu
Open Access
- 7 February 2022
- journal article
- research article
- Published by American Society of Tropical Medicine and Hygiene in The American Journal of Tropical Medicine and Hygiene
- Vol. 106 (4) , 1215-1226
Abstract
: Plasmodium falciparum sporozoite (PfSPZ) Vaccine is composed of radiation-attenuated, aseptic, purified cryopreserved PfSPZ. Multiple clinical trials empirically assessing two to six doses have shown multi-dose priming (two to four doses the first week) to be optimal for protection in both 4- and 16-week regimens. In this randomized, double-blind, normal saline (NS) placebo-controlled trial, four groups (G) of 18- to 32-year-old Equatoguineans received multi-dose priming regimens with or without a delayed final dose at 4 or 16 weeks. The regimens were G1: days 1, 3, 5, 7, and 113; G2: days 1, 3, 5, and 7; G3: days 1, 3, 5, 7, and 29; and G4: days 1, 8, and 29. All doses were 9 × 105 PfSPZ. Tolerability, safety, immunogenicity, and vaccine efficacy (VE) against homologous controlled human malaria infection (CHMI) 6–7 weeks after vaccination were assessed to down-select the best regimen. All four regimens were safe and well tolerated, with no significant differences in adverse events (AEs) between vaccinees (N = 84) and NS controls (N = 20) or between regimens. Out of 19 controls, 13 developed Pf parasitemia by quantitative polymerase chain reaction (qPCR) after CHMI. Only the vaccine regimen administered on study days 1, 8, and 29 gave significant protection (7/21 vaccinees versus 13/19 controls infected, VE 51.3%, P = 0.03, Barnard’s test, two-tailed). There were no significant differences in antibodies against Pf circumsporozoite protein (PfCSP), a major SPZ antigen, between protected and nonprotected vaccinees or controls pre-CHMI. The six controls not developing Pf parasitemia had significantly higher antibodies to blood stage antigens Pf exported protein 1 (PfEXP1) and Pf merozoite surface protein 1 (PfMSP1) than the controls who developed parasitemia, suggesting naturally acquired immunity against Pf limited infections in controls. This study identified a safe, protective, 4-week, multi-dose prime vaccination regimen for assessment in future trials of PfSPZ Vaccine.Keywords
This publication has 40 references indexed in Scilit:
- Controlled human malaria infection by intramuscular and direct venous inoculation of cryopreserved Plasmodium falciparum sporozoites in malaria-naïve volunteers: effect of injection volume and dose on infectivity ratesMalaria Journal, 2015
- Direct venous inoculation of Plasmodium falciparum sporozoites for controlled human malaria infection: a dose-finding trial in two centresMalaria Journal, 2015
- Evaluating controlled human malaria infection in Kenyan adults with varying degrees of prior exposure to Plasmodium falciparum using sporozoites administered by intramuscular injectionFrontiers in Microbiology, 2014
- Controlled Human Malaria Infection of Tanzanians by Intradermal Injection of Aseptic, Purified, Cryopreserved Plasmodium falciparum SporozoitesThe American Journal of Tropical Medicine and Hygiene, 2014
- Protection Against Malaria by Intravenous Immunization with a Nonreplicating Sporozoite VaccineScience, 2013
- Live Attenuated Malaria Vaccine Designed to Protect Through Hepatic CD8 + T Cell ImmunityScience, 2011
- Malaria Blood Stage Suppression of Liver Stage Immunity by Dendritic CellsJournal of Experimental Medicine, 2003
- Antigen-Specific Immunosuppression in Human Malaria Due to Plasmodium falciparumThe Journal of Infectious Diseases, 1986
- IMPAIRMENT OF THE IMMUNE RESPONSE TO VACCINATION AFTER ACUTE MALARIAThe Lancet, 1978
- IMMUNOSUPPRESSION IN CHILDREN WITH MALARIAThe Lancet, 1972